Expect Lupin to test Rs 890: Jitendra Panda

Jitendra Panda, Head Sales - Broking of Capital First Securities told CNBC-TV18, "Pharma sector is doing well, we see lifetime highs in many of the domestic pharma stocks. The Pediatric portfolio of Lupin has grown in US also and they are adding more into that."

"Lupin is a very strong stock in the pharma sector and we see that Rs 860 would be a good level of support where with the stoploss, one could look at Rs 890 as a trading gain for Lupin," he said. At 14:22 hrs Lupin was quoting at Rs 859.15, up Re 1, or 0.12 percent. It has touched an intraday high of Rs 872.15 and an intraday low of Rs 847.65. The share touched its 52-week high Rs 908 and 52-week low Rs 570.50 on 19 July, 2013 and 11 October, 2012, respectively. Currently, it is trading 5.38 percent below its 52-week high and 50.6 percent above its 52-week low. Market capitalisation stands at Rs 38,491.90 crore.